Expression levels of HER2 and MRP1 are not prognostic factors of long‑term survival in 829 patients with esophageal squamous cell carcinoma

Chen,Yong; Zhu,Shuang‑Mei; Xu,Xiao‑Ling; Zhao,An; Hu,Jin‑Lin

doi:10.3892/ol.2015.3975

Expression levels of HER2 and MRP1 are not prognostic factors of long‑term survival in 829 patients with esophageal squamous cell carcinoma

Authors:
- Yong Chen
- Shuang‑Mei Zhu
- Xiao‑Ling Xu
- An Zhao
- Jin‑Lin Hu
View Affiliations

Affiliations: Department of Radio‑Chemotherapy Oncology, Lishui People's Hospital, The Sixth Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 323000, P.R. China, Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, Zhejiang 310022, P.R. China, Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: November 25, 2015 https://doi.org/10.3892/ol.2015.3975
Pages: 745-752

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is the eighth most frequent neoplasm in China. However, the expression levels of human epidermal growth factor receptor 2 (HER2) and multidrug resistance protein 1 (MRP1) in patients with ESCC remain to be determined. In the present study, 829 ESCC cases were evaluated using immunohistochemistry. The association between the expression levels of HER2 and MRP1 and the patient's clinicopathological factors was analyzed using Fisher's exact test or χ2 test. Univariate analysis was performed via Kaplan‑Meier survival curves, while the Cox proportional hazard model was used for multivariate analysis. A significant correlation was observed between the expression levels of HER2 and the patient's gender (P<0.050), tumor size (P=0.013) and venous/lymphatic invasion (P=0.039). However, no significant correlation was identified between the expression levels of MRP1 and the clinicopathological factors of the patients. In univariate analysis, gender, differentiation, depth of invasion, clinical stage, adjuvant radiotherapy or chemotherapy and lymph node metastasis were significantly correlated with progression‑free survival (PFS) and overall survival (OS) in patients with ESCC (P<0.050). The graphical representation of the Kaplan‑Meier estimate curves suggested that the expression levels of HER2 or MRP1 did not exert any influence on prognosis (log‑rank test, P>0.050). In multivariate analysis, tumor location, gender, clinical stage, differentiation and lymph node metastasis were identified as independent factors of prognosis in patients with ESCC (P<0.050). However, the expression levels of HER2 or MRP1 were not independently associated with PFS or OS in these patients. In conclusion, the present large‑scale study demonstrates that the protein expression levels of HER2 and MRP1 does not exert any influence on the prognosis of ESCC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
3	Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW and van Lanschot JJ: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: Five-year survival of a randomized clinical trial. Ann Surg. 246:992–1001. 2007. View Article : Google Scholar : PubMed/NCBI
4	Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M and Rustgi AK: Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 278:1824–1830. 2003. View Article : Google Scholar : PubMed/NCBI
5	Rowinsky EK: Signal events: Cell signal transduction and its inhibition in cancer. Oncologist. 8(Suppl 3): 5–17. 2003. View Article : Google Scholar : PubMed/NCBI
6	Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA and Soares FA: Evaluation of gene amplification and protein expression of HER2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 9:62009. View Article : Google Scholar : PubMed/NCBI
7	Zhan N, Dong WG, Tang YF, Wang ZS and Xiong CL: Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 29:933–940. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chan DS, Twine CP and Lewis WG: Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg. 16:1821–1829. 2012. View Article : Google Scholar : PubMed/NCBI
9	Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A and Fujii H: Frequencies of HER2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 92:1253–1260. 2005. View Article : Google Scholar : PubMed/NCBI
10	Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, et al: Frequent homogeneous HER2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 20:120–129. 2007. View Article : Google Scholar : PubMed/NCBI
11	Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M and Birner P: Expression of HER2 in carcinomas of the esophagus. Am J Surg Pathol. 34:1868–1873. 2010. View Article : Google Scholar : PubMed/NCBI
12	Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, Korc M and Büchler MW: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: Overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg. 23:1010–1018. 1999. View Article : Google Scholar : PubMed/NCBI
13	Suzuki H, Abo S, Kitamura M, Hashimoto M, Izumi K, Terada K and Sugiyama T: Gene amplification of int-2 and erbB in human esophageal cancer: Relationship to clinicopathological variables. Cancer Invest. 15:411–415. 1997. View Article : Google Scholar : PubMed/NCBI
14	Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, Siewert JR and Harbec N: Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer. 73:1785–1794. 1994. View Article : Google Scholar : PubMed/NCBI
15	Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H and van Lanschot JJ: Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 6:290–297. 1999. View Article : Google Scholar : PubMed/NCBI
16	Kato H, Arao T, Matsumoto K, Fujita Y, et al: Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 42:1151–1158. 2013.PubMed/NCBI
17	Thompson SK, Sullivan TR, Davies R and Ruszkiewicz AR: HER2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol. 18:2010–2017. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wang LS, Chow KC, Chi KH, Liu CC, Li WY, Chiu JH and Huang MH: Prognosis of esophageal squamous cell carcinoma: Analysis of clinicopathological and biological factors. Am J Gastroenterol. 94:1933–1940. 1999. View Article : Google Scholar : PubMed/NCBI
19	Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J and Alderson D: Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol. 23:30–35. 1997. View Article : Google Scholar : PubMed/NCBI
20	Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist. 8:411–424. 2003. View Article : Google Scholar : PubMed/NCBI
21	Galimberti S, Marchetti A, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G and Petrini M: Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res. 18:2973–2976. 1998.PubMed/NCBI
22	Yokoyama H, Ishida T, Sugio K, Inoue T and Sugimachi K: Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg Today. 29:1141–1147. 1999. View Article : Google Scholar : PubMed/NCBI
23	Tews DS, Nissen A, Külgen C and Gaumann AK: Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol. 50:227–237. 2000. View Article : Google Scholar : PubMed/NCBI
24	Langer R, Specht K, Becker K, Ewald P, Bekesch M, Sarbia M, Busch R, Feith M, Stein HJ, Siewert JR and Höfler H: Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res. 11:7462–7469. 2005. View Article : Google Scholar : PubMed/NCBI
25	Sobin LH, Gospodarowicz MK and Wittekind C: Title section/chapter. TNM Classification of Malignant Tumours (7th). (Hoboken, NJ). Wiley-Blackwell. 4552009.
26	McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 93:387–391. 2005. View Article : Google Scholar : PubMed/NCBI
27	Xu XL, Zheng WH, Fu ZX, Li ZP, Xie HX, Li XX, Jiang LH, Wang Y, Zhu SM and Mao WM: Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas. Med Oncol. 32:3962015. View Article : Google Scholar : PubMed/NCBI
28	Xu XL, Zheng WH, Tao KY, Li XX, Xu WZ, Wang Y, Zhu SM and Mao WM: p53 is an independent prognostic factor in operable esophageal squamous cell carcinoma: A large-scale study with a long follow-up. Med Oncol. 31:2572014. View Article : Google Scholar : PubMed/NCBI
29	Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al: Quantitative association between HER2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 95:142–153. 2003. View Article : Google Scholar : PubMed/NCBI
30	Owens MA, Horten BC and Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
31	Parums DV: Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc). 50:503–525. 2014. View Article : Google Scholar : PubMed/NCBI
32	Pollock NI and Grandis JR: HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 21:526–533. 2015. View Article : Google Scholar : PubMed/NCBI
33	Kontopodis E, Kentepozidis N, Christophyllakis CH, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, et al: Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 75:153–160. 2015. View Article : Google Scholar : PubMed/NCBI
34	Lee HJ, Seo AN, Kim EJ, Jang MH, Suh KJ, Ryu HS, Kim YJ, Kim JH, Im SA, Gong G, et al: HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol. 142:755–766. 2014. View Article : Google Scholar : PubMed/NCBI
35	Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, et al: Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 32:3307–3329. 2014. View Article : Google Scholar : PubMed/NCBI
36	Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK and Bunn PA Jr: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 11:795–805. 2005.PubMed/NCBI
37	Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel WT, et al: Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 13:441–453. 2008. View Article : Google Scholar : PubMed/NCBI
38	Birner P, Jesch B, Friedrich J, Riegler M, Zacherl J, Hejna M, Wrba F, Schultheis A and Schoppmann SF: Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with HER2 expression. Ann Surg Oncol. 18:3330–3337. 2011. View Article : Google Scholar : PubMed/NCBI
39	Wang G, Zhang W, Jiang W and Luan L: Overexpression of HER2 associated with the progression of esophageal cancer patients. Hepatogastroenterology. 60:1972–1978. 2013.PubMed/NCBI